New Article: Don’t buy AXIM

I did some research on Axim Biotechnologies, and frankly, it’s terrible.  In short, they received a patent that is next-to-worthless, and their value rose 25%, or about $87 million.  Very disproportionate to the actual value of the underlying asset.

Comments

comments